Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Neostigmine Methylsulfate

What is Neostigmine Methylsulfate?

CAS No: 51-60-5

Neostigmine Methylsulfate is a pharmaceutical salt formed by ionic pairing of the active pharmacophore with a carefully selected counter-ion to optimise aqueous solubility, crystallinity, dissolution rate, and solid-state stability relative to the parent free form. Salt selection is a pivotal pharmaceutical development decision influencing polymorphic landscape, hygroscopicity, powder flow, compressibility, and bioavailability. Characterisation of Neostigmine Methylsulfate by XRPD, DSC, TGA, and dynamic vapour sorption is essential to define the approved solid-state form and ensure consistent quality across manufacturing batches.

Health-based exposure limits for Neostigmine Methylsulfate require formal periodic review as new toxicological evidence, clinical safety data, or regulatory agency assessments become available. Pharmaceutical manufacturers are expected to maintain a defined review cycle—typically every 3–5 years or triggered by significant new findings—and to update OEL, PDE,

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Neostigmine Methylsulfate is the methylsulfate salt of neostigmine, a cholinesterase inhibitor commonly supplied for injectable use. Pharmacologically active salts of this kind are handled with attention to occupational exposure and cross-contamination. An assessment of its toxicology helps define limits and controls for shared facilities.

A PDE or ADE sets a health-based limit on daily exposure to Neostigmine Methylsulfate from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

Often, yes, where such information exists. Therapeutic dose data can show the dose range associated with intended and unwanted effects, and may help select or cross-check a point of departure for the limit. They are weighed alongside non-clinical findings, and the way they were used is documented.

A PDE provides the health-based limit for the amount of residual material that may be carried into the next product. Cleaning acceptance criteria, such as the maximum allowable carryover, can then be calculated from it using batch size and the maximum daily dose of the following product. This links cleaning limits to patient safety rather than to arbitrary thresholds.

Relevant evidence may include repeat-dose toxicity, reproductive and developmental toxicity, genotoxicity, carcinogenicity, and pharmacological activity where available. The critical effect is selected based on data quality and relevance. When data are limited, a documented, risk-based approach is used to address the gaps.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Neostigmine Methylsulfate in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Expect a structured document that explains the scientific rationale, shows the calculations and ends with clear recommendations. The work is carried out by certified toxicologists and is designed to be regulatory-ready. The team can confirm the exact scope with you when you use Request Your Assessment or Add to Inquiry on the page.

Although both are health-based, a PDE is usually set for patient exposure to carryover and an OEL for worker exposure, often by inhalation. Each should state its route, units and assumptions. A report may present both, so that cleaning validation and workplace controls each rest on a limit suited to their own purpose.

Reviews are worth planning when new studies or safety information appear, when the process, scale or intended use changes, and when regulators update their guidance. Re-evaluating at these points helps confirm that the health-based limits and the assumptions behind them remain appropriate for the way the substance is handled.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Neostigmine Methylsulfate to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo